NCT00301834 · OUTCOME

Disease-free Survival With Correction of Disease at One Year Post Transplantation

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders · Source last updated 2017-09-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: 1 year post-transplantation

What was measured

Patients deemed "alive and well" at follow-up timepoint later than 1-year post-transplantation

Groups in this outcome

Single Arm - Transplant Pre-conditioning Per Study Protocol

Conditioning with Alemtuzumab, busulfan and fludarabine followed by allogeneic hematopoietic cell transplant.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Single Arm - Transplant Pre-conditioning Per Study Protocol	35

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Single Arm - Transplant Pre-conditioning Per Study Protocol	22	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
22

denoms

counts
group Id
OG000
value
35
units
Participants

description

Patients deemed "alive and well" at follow-up timepoint later than 1-year post-transplantation

groups

description
Conditioning with Alemtuzumab, busulfan and fludarabine followed by allogeneic hematopoietic cell transplant.
id
OG000
title
Single Arm - Transplant Pre-conditioning Per Study Protocol

param Type

NUMBER

reporting Status

POSTED

time Frame

1 year post-transplantation

title

Disease-free Survival With Correction of Disease at One Year Post Transplantation

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice